Pharmaceutical giant
“Our effective tax rate is now expected to be between 17.5% and 18.5% for the full year, much higher than 2023, largely due to the impact of OECD Pillar 2 as well as the non-deductible nature of the recently announced NM26 bispecific antibody acquisition,” Joseph Wolk, Johnson & Johnson CFO, said on an earnings call Wednesday. J&J agreed to buy the rights ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.